Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Source abstract
Abstract
In the past two decades, we have witnessed the discovery and development of many potent and efficacious proteolysis-targeting chimera (PROTAC) degraders, with several in phase I/II clinical trials. However, achieving good oral bioavailability for these degraders remains one of the biggest challenges, given the fact that PROTACs are often “beyond rule of 5” for small-molecule drugs because of their higher molecular weight and other poor physiochemical properties. In this review, we focus on the current efforts in the discovery and development of various orally available anti-cancer PROTAC degraders, and comprehensively summarize the strategies applied to this end. We believe that the strategies summarized here may provide a reference for future discovery of new oral-available PROTAC degraders for the treatment of various human diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Protein Degradation and Inhibitors · Multiple Myeloma Research and Treatments · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins10.1021/ja100691p ↗
2. Small-molecule PROTACS: new approaches to protein degradation10.1002/anie.201507978 ↗
3. Modular PROTAC design for the degradation of oncogenic BCR-ABL10.1002/anie.201507634 ↗
4. Phthalimide conjugation as a strategy for in vivo target protein degradation10.1126/science.aab1433 ↗
5. Catalytic in vivo protein knockdown by small-molecule PROTACs10.1038/nchembio.1858 ↗
6. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase10.1038/nature16979 ↗
7. Induced protein degradation: an emerging drug discovery paradigm10.1038/nrd.2016.211 ↗
8. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?10.1021/acs.jmedchem.7b01272 ↗
9. Small-molecule modulation of protein homeostasis10.1021/acs.chemrev.7b00077 ↗
10. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation10.1073/pnas.141230798 ↗
11. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics10.1016/j.bmcl.2008.07.114 ↗
12. Targeting nuclear receptors with PROTAC degraders10.1016/j.mce.2019.110452 ↗
13. Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders10.1021/acs.jmedchem.9b00846 ↗
14. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression10.1021/acs.jmedchem.8b00909 ↗
15. Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)10.1021/acs.jmedchem.8b01572 ↗
16. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity10.1038/s41591-019-0668-z ↗
17. Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein10.1021/acs.jmedchem.9b01530 ↗
18. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo10.1016/j.ccell.2019.10.002 ↗
19. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer10.1073/pnas.1521738113 ↗
20. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation10.1038/s41467-017-00954-1 ↗
21. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD410.1016/j.chembiol.2015.05.009 ↗
22. The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer
23. ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer10.1200/JCO.2019.37.7_suppl.259 ↗
24. ARV-110: an androgen receptor PROTAC degrader for prostate cancer10.1158/1538-7445.AM2018-5236 ↗
25. First targeted protein degrader hits the clinic10.1038/d41573-019-00043-6 ↗
26. PROTAC cell permeability and oral bioavailability: a journey into uncharted territory10.4155/fmc-2021-0208 ↗
27. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: recent progress and future challenges10.1016/j.bmcl.2019.04.030 ↗
28. KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition10.1158/1538-7445.AM2019-LB-272 ↗
29. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective10.1016/j.drudis.2020.07.013 ↗
30. First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo10.1016/j.ejmech.2020.112903 ↗
31. Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo10.1016/j.apsb.2020.11.001 ↗
32. Rational control of molecular properties is mandatory to exploit the potential of PROTACs as oral drugs10.1021/acsmedchemlett.1c00298 ↗
33. HSK26784: an oral PROTAC-BTK degrader for multiple B lymphocyte derived malignancies
34. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib10.1016/j.ejmech.2021.113335 ↗
35. Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer10.1021/acs.jmedchem.1c00882 ↗
36. Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer10.1021/acs.jmedchem.1c00900 ↗
37. Targeting protein kinases degradation by PROTACs10.3389/fchem.2021.679120 ↗
38. The PROTAC gold rush10.1038/s41587-021-01173-2 ↗
39. Strategies for designing proteolysis targeting chimaeras (PROTACs)10.1002/med.21877 ↗
40. PROTAC targeted protein degraders: the past is prologue10.1038/s41573-021-00371-6 ↗
41. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
42. PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
43. PROTACs- a game-changing technology10.1080/17460441.2019.1659242 ↗
44. The PROTAC technology in drug development10.1002/cbf.3369 ↗
45. Targeted protein degradation by PROTACs10.1016/j.pharmthera.2017.02.027 ↗
46. Targeted protein degradation: from chemical biology to drug discovery10.1016/j.chembiol.2017.05.024 ↗
47. Chemical protein degradation approach and its application to epigenetic targets10.1002/tcr.201800032 ↗
48. Degradation of proteins by PROTACs and other strategies10.1016/j.apsb.2019.08.001 ↗
49. Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery10.1039/C9RA03423D ↗
50. PROTACs: great opportunities for academia and industry10.1038/s41392-019-0101-6 ↗
51. Opportunities and challenges10.1021/acsmedchemlett.9b00597 ↗
52. PROTACs: an emerging targeting technique for protein degradation in drug discovery10.1002/bies.201700247 ↗
53. Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs10.1021/acscentsci.9b00713 ↗
54. 3-Fluoro-4-hydroxyprolines: synthesis, conformational analysis, and stereoselective recognition by the VHL E3 ubiquitin ligase for targeted protein degradation10.1021/jacs.8b05807 ↗
55. Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation10.1021/acs.jmedchem.1c01069 ↗
56. Harnessing the E3 ligase KEAP1 for targeted protein degradation10.1021/jacs.1c04841 ↗
57. Discovery of a novel BCL-XL PROTAC degrader with enhanced BCL-2 inhibition10.1021/acs.jmedchem.1c00517 ↗
58. Phenyl-glutarimides: alternative cereblon binders for the design of PROTACs10.1002/anie.202108848 ↗
59. Small-molecule PROTAC degraders of the bromodomain and extra terminal (BET) proteins - a review10.1016/j.ddtec.2019.04.001 ↗
60. Discovery of a highly potent and selective degrader targeting hematopoietic prostaglandin D synthase via in silico design10.1021/acs.jmedchem.1c01206 ↗
61. Development of BromoTag: a "Bump-and-Hole"-PROTAC system to induce potent, rapid, and selective degradation of tagged target proteins10.1021/acs.jmedchem.1c01532 ↗
62. Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity10.1038/s41589-021-00878-4 ↗
63. Proteolysis-targeting chimera (PROTAC) modification of dovitinib enhances the antiproliferative effect against FLT3-ITD-positive acute myeloid leukemia cells10.1021/acs.jmedchem.1c00996 ↗
64. Efficient targeted degradation via reversible and irreversible covalent PROTACs10.1021/jacs.9b13907 ↗
65. Achieving in vivo target depletion through the discovery and optimization of benzimidazolone BCL6 degraders10.1021/acs.jmedchem.9b02076 ↗
66. Small-molecule-induced polymerization triggers degradation of BCL610.1038/s41586-020-2925-1 ↗
67. Gluing proteins for targeted degradation10.1016/j.ccell.2020.12.020 ↗
68. Structural basis of PROTAC cooperative recognition for selective protein degradation10.1038/nchembio.2329 ↗
69. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis10.1039/C0MB00104J ↗
70. Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions10.1016/j.addr.2016.04.029 ↗
71. Understanding the challenge of beyond-rule-of-5 compounds10.1016/j.addr.2016.05.016 ↗
72. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings10.1016/S0169-409X(00)00129-0 ↗
73. Non-acidic bifunctional benzothiazole-based thiazolidinones with antimicrobial and aldose reductase inhibitory activity as a promising therapeutic strategy for sepsis10.1007/s00044-021-02778-7 ↗
74. Androgen receptor: past, present and future10.2174/1389450111314040002 ↗
75. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer10.1016/j.ejmech.2019.03.041 ↗
76. An androgen receptor N-terminal domain antagonist for treating prostate cancer10.1172/JCI66398 ↗
77. Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
78. Androgen-receptor gene structure and function in prostate cancer10.1007/BF00184606 ↗
79. Androgen receptor structural and functional elements: role and regulation in prostate cancer10.1210/me.2007-0223 ↗
80. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer10.3389/fonc.2019.00801 ↗
81. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance10.3390/cancers9060067 ↗
82. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer10.2147/DDDT.S69433 ↗
83. Mortality results from a randomized prostate-cancer screening trial10.1056/NEJMoa0810696 ↗
84. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells10.1002/pros.22535 ↗
85. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis10.1200/JCO.2005.03.4777 ↗
86. Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists10.1016/j.bmc.2012.02.005 ↗
87. Metastatic prostate cancer remains incurable, why?10.1016/j.ajur.2018.11.005 ↗
88. Overcoming mutation-based resistance to antiandrogens with rational drug design10.7554/eLife.00499 ↗
89. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance10.1038/s42003-018-0105-8 ↗
90. Arvinas unveils PROTAC structures10.47287/cen-09914-scicon1 ↗
91. Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands10.1021/acs.jmedchem.9b01393 ↗
92. A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro tumor growth in vivo10.1016/j.neo.2020.07.002 ↗
93. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
94. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer10.1021/acs.jmedchem.8b01631 ↗
95. Targeting estrogen receptor alpha for degradation with PROTACs: a promising approach to overcome endocrine resistance10.1016/j.ejmech.2020.112689 ↗
96. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance10.1016/j.ejmech.2020.112190 ↗
97. Discovery of a brigatinib degrader SIAIS164018 with destroying metastasis-related oncoproteins and a reshuffling kinome profile10.1021/acs.jmedchem.1c00373 ↗
98. HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations10.1158/1535-7163.MCT-21-0835 ↗
99. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 1 degradation in vivo
100. Light-induced control of protein destruction by opto-PROTAC10.1126/sciadv.aay5154 ↗